Perifosine in Treating Patients With Recurrent Prostate Cancer

Inclusion Criteria

• •Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate
• •Patients must have a rising PSA \>= 2.0 following a nadir after local curative therapy (either radical prostatectomy and/or pelvic radiation) with no clinical or radiographic evidence of metastatic disease; PSA \>= 2.0 elevation must be confirmed by two consecutive increases, each measured at least 2 weeks apart; only patients with a biochemical (PSA) recurrence with no physical exam or radiographic evidence of local or distant relapse are eligible
• •Prior hormonal therapy in the form of neoadjuvant or adjuvant therapy is allowed as long as neither lasted for more than 9 months; androgen deprivation therapy must have been completed at least one year prior to registration; patients could not have had a rising PSA at the time that neoadjuvant or adjuvant therapy was stopped
• •Life expectancy of greater than 3 months
• •Karnofsky performance status \> 60%
• •Leukocytes \>= 3,000/uL
• •Absolute neutrophil count \>= 1,500/uL
• •Platelets \>= 100,00/uL
• •Total bilirubin =\< 1.5 mg/dL
• •AST (SGOT)/ALT (SGPT) =\< 2.5 x institutional upper limit of normal
• •Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min
• •Computed tomography scan or MRI of the pelvis negative for metastatic disease within 3 months prior to registration
• •Bone scan negative for metastatic disease within 3 months prior to registration
• •Chest PA and lateral films negative for metastatic disease within 3 months prior to registration
• •Prior vaccine therapy is allowed if completed at least 6 months prior to registration
• •Men enrolled in this trial must agree to use adequate contraception prior to study entry and for the duration of study participation
• •Ability to understand and the willingness to sign a written informed consent document